The Princess Máxima Center for Pediatric Oncology is a research hospital concentrating healthcare, research and education of pediatric cancer in a single location in Utrecht. The institute aims to provide the highest level of care for all children with cancer and has the ambition to cure all children of cancer and improve quality of life. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.
The Belderbos Group
The Belderbos Group is looking for an enthusiastic, highly motivated postdoctoral researcher with interest in translational hematopoietic stem cell biology and experience or willingness to learn single-cell mRNA sequencing technology.
The overall aim of our group is to unravel the basic mechanisms by which human hematopoietic stem cells (re-)generate blood, and to translate this knowledge into clinical therapies to improve hematopoiesis in children with intrinsic or acquired bone marrow failure, or in those undergoing HSCT. The Belderbos group was recently established in the Princess Máxima Center for Pediatric Oncology, the Dutch national hospital for childhood cancer. This institute has the ambition to cure every child with cancer, while providing optimal quality of life. Hereto, scientific research and clinical care are closely integrated, providing a unique opportunity for translational research. In our group, we apply innovative single-cell technology to samples of pediatric patients. We collaborate closely with pediatric stem cell transplant physicians and several other research groups, both within the Princess Máxima Center and (inter-)nationally. Core values in our group are collaboration, curiosity and clinical impact.
Hematopoietic stem/progenitor cells (HSPCs) orchestrate the lifelong production of all mature blood cell types. These very properties, i.e. long-term self-renewal and multi-lineage differentiation, render HSCs highly valuable for therapeutic purposes. In fact, HSC transplantation (HSCT) is performed in over 30.000 patients annually, as a curative therapy for various diseases, including pediatric leukemia.
Despite their crucial role in native hematopoiesis and therapeutic application, the phenotype of human HSCs and the signaling pathways regulating their behavior remain largely unknown. This project aims to use single-cell mRNA sequencing technology to unravel the composition of the human hematopoietic system, during normal childhood, upon chemotherapeutic treatment and after HSCT.
This project includes multi-parameter flow cytometry, single-cell RNA sequencing and genomics, using cell lines as well as primary patient samples.
- PhD degree in biomedical sciences, molecular/cellular biology, or an equivalent thereof, and a clear interest in translational cancer research
- It is important that the candidate has a proven affinity with, or a strong desire and ability to learn, single-cell RNA sequencing analysis.
- Prior experience with R, advanced statistics, flow cytometry, next generation sequencing, molecular and cellular biology would be optimal
- Pioneer, who is willing to contribute to the development of our research group
- Team player who is willing to collaborate closely with scientists and clinicians
- Excellent communication and presentation skills
- Ambition to pursuit a career in science
The Princess Máxima Center for Pediatric Oncology is a new research hospital concentrating healthcare, research and education with regard to cancer in children in a single location in Utrecht. The institute aims to provide the highest level of care for all children with cancer, with optimal quality of life. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.
We offer a challenging position in an international, multidisciplinary research environment, which combines clinical oncology, stem cell biology and single-cell genomics.
The position is based on 0.8-1.0 fte, based on 36 hours per week. You will start on a temporary position for the duration of one year, which –upon satisfactory completion of the first year- will be extended for a total of three years. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.
Apply for this position?
You can apply for this position until the 1st of October, by pressing the “apply” button on this screen. Potential candidates will be invited for interviews in October.
Contact and application
For more information about the vacancy, you are welcome to contact Dr. Mirjam Belderbos (firstname.lastname@example.org).
Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.Solliciteer direct